{
    "abstract": "Thrombocytopenia is common in critically ill patients treated with continuous renal replacement therapy and decreases in platelets following continuous renal replacement therapy initiation have been associated with increased mortality. Platelets play a role in innate and adaptive immunity, making it plausible that decreases in platelets following continuous renal replacement therapy initiation predispose patients to development of infection. Our objective was to determine if greater decreases in platelets following continuous renal replacement therapy correlate with increased rates of secondary infection.\nRetrospectivecohort analysis.\nThis study uses a continuous renal replacement therapy database from Mayo Clinic (Rochester, MN), a tertiary academic center.\nAdult patients who survived until ICU discharge and were on continuous renal replacement therapy for less than 30 days were included. A subgroup analysis was also performed in patients with thrombocytopenia (platelets < 100 \u00d7 103/\u00b5L) at continuous renal replacement therapy initiation.\nThe primary predictor variable was a decrease in platelets from precontinuous renal replacement therapy levels of greater than 40% or less than or equal to 40%, although multiple cut points were analyzed. The primary outcome was infection after ICU discharge, and secondary endpoints included post-ICU septic shock and post-ICU mortality. Univariable, multivariable, and propensity-adjusted analyses were used to determine associations between the predictor variable and the outcomes.\nAmong 797 eligible patients, 253 had thrombocytopenia at continuous renal replacement therapy initiation. A greater than 40% decrease in platelets after continuous renal replacement therapy initiation was associated in the multivariable-adjusted models with increased odds of post-ICU infection in the full cohort (odds ratio, 1.49; CI, 1.02-2.16) and in the thrombocytopenia cohort (odds ratio, 2.63; CI, 1.35-5.15) cohorts.\nPlatelet count drop by greater than 40% following continuous renal replacement therapy initiation is associated with an increased risk of secondary infection, particularly in patients with thrombocytopenia at the time of continuous renal replacement therapy initiation. Further research is needed to evaluate the impact of both continuous renal replacement therapy and platelet loss on subsequent infection risk.",
    "authors": [
        {
            "affiliation": "Division of Nephrology, Department of Medicine, University of, Iowa Carver College of Medicine, Iowa City, IA.\nCenter for Access & Delivery Research & Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, IA.",
            "firstname": "Benjamin R",
            "initials": "BR",
            "lastname": "Griffin"
        },
        {
            "affiliation": "Division of Nephrology, Department of Medicine, University of, Iowa Carver College of Medicine, Iowa City, IA.",
            "firstname": "Chaorong",
            "initials": "C",
            "lastname": "Wu"
        },
        {
            "affiliation": "Division of Infectious Disease, Department of Medicine, Mayo Clinic, Rochester, MN.",
            "firstname": "John C",
            "initials": "JC",
            "lastname": "O'Horo"
        },
        {
            "affiliation": "Division of Renal Diseases & Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.",
            "firstname": "Sarah",
            "initials": "S",
            "lastname": "Faubel"
        },
        {
            "affiliation": "Division of Nephrology, Department of Medicine, University of, Iowa Carver College of Medicine, Iowa City, IA.\nCenter for Access & Delivery Research & Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, IA.",
            "firstname": "Diana",
            "initials": "D",
            "lastname": "Jalal"
        },
        {
            "affiliation": "Division of Nephrology and Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.",
            "firstname": "Kianoush",
            "initials": "K",
            "lastname": "Kashani"
        }
    ],
    "conclusions": null,
    "copyrights": "Copyright \u00a9 2020 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.",
    "doi": "10.1097/CCM.0000000000004763",
    "journal": "Critical care medicine",
    "keywords": [],
    "methods": null,
    "publication_date": "2020-12-30",
    "pubmed_id": "33372743\n26162677\n23499048\n28542272\n31540789\n23133643\n21152901\n21921612\n27113694\n21436837\n30585829\n31816284\n25444488\n27380175\n24824815\n29693303\n14636006\n10921599\n27812064\n22592187\n9096808\n11961397\n31233518\n29508077\n32007252\n28957635\n25301709\n28943342\n18759963",
    "results": "Among 797 eligible patients, 253 had thrombocytopenia at continuous renal replacement therapy initiation. A greater than 40% decrease in platelets after continuous renal replacement therapy initiation was associated in the multivariable-adjusted models with increased odds of post-ICU infection in the full cohort (odds ratio, 1.49; CI, 1.02-2.16) and in the thrombocytopenia cohort (odds ratio, 2.63; CI, 1.35-5.15) cohorts.",
    "title": "The Association of Platelet Decrease Following Continuous Renal Replacement Therapy Initiation and Increased Rates of Secondary Infections.",
    "xml": "<Element 'PubmedArticle' at 0x788502e7d080>"
}